Adverum Biotechnologies is a clinical-stage gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from serious ocular and rare diseases. Leveraging its proprietary adeno-associated virus (AAV)-based directed evolution platform, Adverum aims to engineer highly efficient and targeted gene therapies. Their primary focus includes treatments for conditions like wet age-related macular degeneration (wet AMD) and other ophthalmological disorders with significant unmet medical needs. The company is committed to advancing its pipeline through rigorous clinical trials and innovative research to bring potentially transformative therapies to patients.
The headquarters serves as the central hub for Adverum's research and development, clinical operations, corporate administration, and strategic decision-making.
State-of-the-art laboratory facilities for gene therapy research, including vector development and process sciences, along with modern office spaces designed to foster collaboration and innovation.
Adverum promotes a work culture centered on scientific rigor, innovation, patient focus, and collaboration. Employees are driven by the potential to make a significant impact on patients' lives through cutting-edge gene therapy.
The Redwood City headquarters is pivotal for Adverum's mission, housing the core scientific and operational teams that drive the discovery, development, and potential commercialization of their gene therapy candidates.
Adverum Biotechnologies' primary operations, including research, development, and corporate functions, are centered in the United States. While their physical presence is U.S.-based, their clinical trials may involve international sites, and their therapeutic focus on globally prevalent diseases like wet AMD implies a long-term vision for global patient impact and potential market reach upon successful drug approvals.
100 Cardinal Way
Redwood City
CA
USA
Address: 100 Cardinal Way, Redwood City, CA 94063
Serves as the global R&D and corporate hub.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Adverum' leadership includes:
Adverum has been backed by several prominent investors over the years, including:
Over the past 12 months, Adverum Biotechnologies has seen key appointments strengthening its executive team, including a new Chief Medical Officer and a new Chief Business and Strategy Officer, alongside a role expansion for its General Counsel to COO. There was also a departure of the Chief Development Officer.
Discover the tools Adverum uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Adverum Biotechnologies commonly uses the email format combining the first initial and last name. Other formats might exist but this is the most prevalent.
[first_initial][last]@adverum.com
Format
lfischer@adverum.com
Example
85%
Success rate
GlobeNewswire • May 21, 2024
Adverum Biotechnologies announced the appointment of Gustavo A. Diaz, M.D., as chief medical officer (CMO), effective May 20, 2024. Dr. Diaz will lead the company’s clinical development strategy and operations for its novel gene therapies....more
GlobeNewswire • May 9, 2024
Adverum reported financial results for Q1 2024, highlighting progress in its clinical programs, including Ixo-vec for wet AMD, and outlined key upcoming milestones. The company also noted the termination of employment for its Chief Development Officer, Rabia Gurses Ozden, M.D., effective June 7, 2024....more
GlobeNewswire • January 29, 2024
Adverum announced the expansion of Peter Soparkar's role to Chief Operating Officer (COO), in addition to his existing responsibilities as General Counsel and Corporate Secretary. This change aims to enhance operational execution as the company advances its clinical programs....more
GlobeNewswire • November 2, 2023
Adverum appointed Setareh Seyedzadeh as Chief Business and Strategy Officer to lead business development, corporate strategy, and portfolio planning....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Adverum, are just a search away.